Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
D NyholmAnders Johansson

Abstract

Infusion of levodopa/carbidopa intestinal gel (Duodopa ; Abbott) was introduced in Sweden in 1991 as an experimental treatment in advanced Parkinson's disease and obtained EU approval in 2004. There is compelling evidence for short-term use of this treatment; however, long-term data are scarce. A retrospective review of medical records was performed. The primary objective was to assess the duration of treatment for all Swedish patients starting long-term levodopa/carbidopa gel therapy between January 1991 and June 2008. Secondary aims were to study demographics, treatment with anti-Parkinson's disease drugs and other concomitant medications, and reasons for discontinuation of levodopa/carbidopa gel. Of 150 identified patients, 135 were included in the study. On average, patients were 49 years at diagnosis of Parkinson's disease and 63 years when infusion therapy was initiated. The median treatment time on infusion was 3.4 years (range, 0-16 years). The restricted mean treatment time was nearly 8 years; 81 patients were still on treatment at the end of the study. Levodopa was used as monotherapy in a majority of patients. Dosage of the drug was stable over time. Thirty-one patients discontinued infusion prior to the cutoff date ...Continue Reading

References

Jun 5, 2003·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
Dec 17, 2004·Clinical Neuropharmacology·Dag Nyholm, Sten-Magnus Aquilonius
Nov 9, 2005·Neurology·Dag NyholmIngela Nilsson Remahl
May 30, 2006·Parkinsonism & Related Disorders·J WestinS E Palhagen
Mar 1, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Mariese A HelyJohn G L Morris
Apr 3, 2008·Clinical Neuropharmacology·Dag NyholmSten-Magnus Aquilonius
Mar 3, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·David Devos, UNKNOWN French DUODOPA Study Group
May 9, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Holger HonigK Ray Chaudhuri
Oct 6, 2009·Applied Health Economics and Health Policy·Ivar Sønbø KristiansenDag Isacson
Nov 17, 2009·Lancet Neurology·Walter MaetzlerDaniela Berg
Aug 27, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Peter P UrbanJoachim Weis
Oct 12, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Iria Cabo LópezVicenta Sánchez Bernardos
Oct 22, 2010·Neurology·Christopher G GoetzGlenn T Stebbins
Mar 1, 2011·Current Medical Research and Opinion·H H Fernandez, P Odin

❮ Previous
Next ❯

Citations

Mar 22, 2013·CNS Drugs·Fabienne Sprenger, Werner Poewe
Dec 18, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Fabrizio Stocchi
Nov 26, 2015·Expert Opinion on Pharmacotherapy·Lauren C Seeberger, Robert A Hauser
Mar 13, 2014·Expert Opinion on Drug Safety·Wolfgang H Jost
Apr 1, 2016·Clinical and Translational Gastroenterology·Michael EpsteinJanet Benesh
Apr 15, 2016·Neurodegenerative Disease Management·Diego Santos GarcíaNatividad Mariscal Pérez
Jan 31, 2017·Acta Neurologica Scandinavica·E Dietrichs, P Odin
Apr 30, 2017·Clinical Neuropharmacology·Ignacio RegidorJuan Carlos Martinez Castrillo
Mar 24, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Hubert H FernandezAlberto J Espay
Feb 8, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Onanong JitkritsadakulRoongroj Bhidayasiri
Sep 10, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Karen L Eskow JaunarajsRandall W Moreadith
Dec 24, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Anthony E LangJordan Dubow
Feb 2, 2018·NPJ Parkinson's Disease·David G StandaertKrai Chatamra
Feb 6, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Haidar S DafsariUNKNOWN EUROPAR and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group
Oct 27, 2015·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A MerolaL Lopiano
Jan 18, 2014·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V Schapira
Dec 10, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M ZibettiL Lopiano
Dec 30, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Hubert H FernandezAlberto J Espay
Mar 24, 2016·Movement Disorders Clinical Practice·Jonathan TimpkaPer Odin
Nov 6, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Maria PapathanouAndrew C McCreary
Apr 5, 2017·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·A A SkorometsS N Illarioshkin
Nov 20, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V Schapira, E K Tan
Mar 28, 2017·Therapeutic Advances in Neurological Disorders·Johan Virhammar, Dag Nyholm
Aug 18, 2020·Neuropsychiatric Disease and Treatment·Viorelia Adelina ConstantinMihaela Simu
Jan 18, 2018·Neurología : publicación oficial de la Sociedad Española de Neurología·D Santos-GarcíaF Grandas
Apr 4, 2021·Journal of Personalized Medicine·Mezin ÖthmanDag Nyholm
May 6, 2021·Brain and Behavior·Monica ScharfenortPer Odin
Apr 21, 2021·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Jennifer TaherAlfonso Fasano

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.